Moggs Jonathan G, Deavall Damian G, Orphanides George
Syngenta CTL, Alderley Park, Cheshire, United Kingdom.
Bioessays. 2003 Mar;25(3):195-9. doi: 10.1002/bies.10249.
Osteoporosis is characterized by reduced bone density and strength. Bone mass peaks between age 30 and 40 and then declines. This can be accelerated by factors including menopause and insufficient dietary calcium. Hormone replacement therapy (HRT) is currently the standard treatment for osteoporosis. However, growing concern over potential side effects of HRT has driven a search for alternative therapies. A recent report 1 reveals a potential alternative to HRT: a gender-neutral synthetic steroid that increases bone mass and strength without affecting reproductive organs. This compound acts via a novel extranuclear sex steroid receptor signaling mechanism that has important implications for nuclear receptor biology and human health.
骨质疏松症的特征是骨密度和强度降低。骨量在30至40岁之间达到峰值,然后下降。包括更年期和饮食中钙摄入不足等因素会加速这种情况。激素替代疗法(HRT)是目前治疗骨质疏松症的标准方法。然而,对HRT潜在副作用的日益关注促使人们寻找替代疗法。最近的一份报告1揭示了一种HRT的潜在替代方法:一种不影响生殖器官但能增加骨量和强度的中性合成类固醇。这种化合物通过一种新的核外性类固醇受体信号传导机制起作用,这对核受体生物学和人类健康具有重要意义。